Objective: Tobacco smoking after lower extremity revascularization for claudication has repeatedly been shown to increase the risk of adverse events, such that many vascular specialists consider that refusal to abstain from smoking constitutes a major contraindication to open surgical bypass or endovascular intervention.
Results: Among patients referred during a recent 64-month period with vasculogenic claudication, 94 were actively smoking compared with 217 who were not. The DA model predicted that if the patients who smoked were to discontinue smoking, the best therapy would be bypass surgery for 77% and endovascular intervention for 17%. However, despite at least doubling the risks with intervention in the patients who continue to smoke, the DA model still predicted that 78% and 9% would fare better with open surgical or endovascular intervention, respectively. Among actively smoking patients, open surgical (3%) or endovascular (4%) therapies were initially performed in few patients, whereas 93% were offered only medical therapy. Among initial nonsmokers 
Conclusions:
Patients with claudication who smoke may be denied the symptom improvement associated with revascularization, yet recidivism for smoking also occurs among patients who have stopped smoking in order to receive revascularization. The strategy not to directly revascularize patients with claudication who continue to smoke does not appear to maximize patient midterm QoL. (J Vasc Surg 2017; 65:128-35.) Smoking is a risk factor demonstrated to increase the odds of developing claudication as a symptom of peripheral arterial disease (PAD). [1] [2] [3] [4] Claudicating patients who smoke progress to critical limb ischemia at a rate of 2% to 3% annually, and although <1% per year of nonsmokers progress to major lower extremity amputation, this rate is more than doubled in smokers. [5] [6] [7] In addition, smoking has been shown to be an independent predictor of failure of treatment for patients with PAD. [8] [9] [10] The risk of postoperative graft failure, such as loss of patency or limb loss, is significantly higher in smokers who undergo direct revascularization via a bypass operation. 11 One study reported that limb loss via amputation occurred #1 year after an open bypass in 10% of patients who were smokers vs in only 1% of nonsmokers.
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Cognizant of this apparent risk, the option to directly revascularize patients with claudication by an endovascular procedure or open bypass operation is often withheld from patients who continue to smoke. Yet in light of the recognized harm associated with smoking, it is actually surprising that as many as 41% of lower extremity bypass operations in a recent Vascular Study Group of New England study for all indications were performed in current smokers. 13 Considering the otherwise low risk of limb loss for patients with PAD symptoms limited to claudication, that a full 53% of claudicating patients undergoing infrainguinal bypass in the Carolinas were active smokers at the time of intervention is even more concerning. 1, 12 Decisions on treatment for a patient with PAD are acknowledged to be very complex, and many underlying factors must be taken into account. Although it is ultimately up to the surgeon to propose a plan of treatment, the patient may or may not choose to follow the advice. To assist with complex decision making for lower extremity arterial occlusive disease, a computerized decision analysis (DA) tool has demonstrated that patients with PAD enjoy better outcomes if they follow the treatment suggested by the model. 14 Using this model, Brothers 15 determined that nearly a quarter of the discordance between actual treatment and the DA model appeared to be due failure to revascularize patients who continue to smoke.
The objective of the current study was therefore to further investigate whether claudicating patients who continue to smoke might enjoy a higher quality of life (QoL) if offered direct revascularization despite an increased risk of late failure of patency or need for amputation. The hypothesis to be tested was patient health-related QoL in patients with claudication who do not undergo revascularization because they refuse to abstain from tobacco compared with how they might fare with direct revascularization. A Markov DA model was used to compare the options of direct revascularization vs medical therapy only in smokers with claudication. In addition, the calculated QoL (cQoL) was used to compare results of intervention for smoking patients with those of smokers who did not undergo intervention as well as with nonsmoking patients.
METHODS
The protocol for this retrospective cohort study, including waiver of consent, was approved by the Medical University of South Carolina Institutional Review Board and the Ralph H. Johnson Department of Veterans Affairs Medical Center Research and Development Committee.
Research design. The primary outcome of interest was the results of the DA model in terms of predicted QoL. The secondary outcomes for patients who underwent direct revascularization were cQoL, limb salvage, and amputation-free survival (AFS). Patients were compared according to whether they were smokers or nonsmokers at the initial encounter with the vascular surgeon. The smokers were compared according to whether or not they underwent direct revascularization. Patients were further compared according to whether they began/ resumed smoking during the time between the initial visit and their most recent follow-up appointment. Nonsmokers were defined as those who had never smoked or had ceased smoking for a minimum of 30 days before the initial encounter.
Data collection. All patients referred to one vascular surgeon during a 54-month period for management of symptomatic PAD with claudication were eligible for inclusion in the study, including patients from a tertiary referral university hospital and a Veterans Administration hospital. The study excluded patients with critical limb ischemia at the initial visit, confirmed by ankle-brachial indices <0.40 and rest pain or tissue loss.
The medical records of patients included in the study were examined to gather pertinent information related to demographics, comorbidities, surgical history, smoking history, and treatment received #3 months of the initial visit. The decision to proceed with direct open or endovascular surgical revascularization was based on usual clinical care with consideration of failure of prior exercise or oral medical therapy, severity of symptoms, associated medical comorbidities, arterial anatomy, and smoking status. The standard practice was not to offer revascularization to actively smoking patients. These data were used in the DA model to predict the best treatment type for each patient.
The actual treatment received and the development of postoperative rest pain, gangrene, ischemic ulcer, reintervention, loss of graft patency, above-ankle amputation, or death at the most recent follow-up were also recorded. Graft patency was used with limb salvage to calculate the outcome of major adverse limb event, whereas patient survival was used with limb salvage to calculate the outcome of AFS.
Patients who received medical therapy only were advised to stop smoking, prescribed aspirin (81 mg) by mouth daily, prescribed a statin medication (various types and dose), and advised to practice nonsupervised exercise therapy with walking for 30 minutes at least three times per week. Supervised exercise therapy was not available, and compliance with this medical therapy other than smoking was not monitored.
DA model. The Markov-based, individualized vascular surgery DA model has previously been described. 5 Briefly, the probability that any one of the three different treatmentsdmedical therapy only, open surgery, or endovascular interventiondwould result in a specific outcome was estimated by an experienced surgeon based on clinical experience and published literature according to the patient's age, anatomy, and comorbid conditions. Utility scores were assigned for each outcome. Derivation of these utility values using a visual analog scale in patients with symptomatic PAD has previously been described and is provided in Supplementary Utility values were discounted at an annual rate of 5%, with negative utilities of À0.005 or À0.001 assigned for the performance of each additional open operation or endovascular intervention, respectively. The model was rolled back on a monthly cycle and terminated when 99.9% of the model was absorbed within the transitional state for death or at a maximum of 600 cycles (corresponding to 50 years after entry) in the unlikely event that the first condition was not met. Sensitivity analysis was not performed for each patient for alternative outcome probability estimates because variation in the model is provided by the use of individual predictions for each individual patient and commitment to a single prediction estimate at the time and point of care was considered necessary for this exercise. The treatment that the DA model predicted to result in the highest QoL was considered to be the best treatment selected by the model. cQoL scores. For this retrospective study derived from medical record documentation, prospective assessment of patient QoL was not feasible. Instead, cQoL scores were assigned according to patient symptoms, limb perfusion status, limb salvage, type of intervention, wound healing, ambulatory ability, and the requirement for subsequent intervention and were considered to represent a generic measure of QoL 15 These cQoL scores were based on prior published utility analysis of patient preferences for outcome, with anchors of 1.000 (perfect health), 0.732 (claudication), 0.456 (critical limb ischemia), and 0.000 (death) using visual analog scale methods 14 (Supplementary Table I , online only). Scores were assigned preoperatively and at each follow-up encounter according to symptoms, physical findings, and treatment results. cQOL values for each patient were assumed to be static over time, unless there was a change in patient ischemic symptoms, ambulatory ability, or reintervention status, at which time the values were assumed to change as determined from patient history. Patients who died during the course of follow-up were assigned a monthly score of 0.000 for each subsequent month after death until the date of study terminus. This allowed the outcome to be counted not only in the initial months after study entry in calculation of the average cQoL but also acknowledged limitations in the long-term benefit of improvement in cQoL for the entire group. To account for other lower extremity nonvascular patient comorbidities that might be expected to lead to diminished QoL, the cQoL scores were discounted at 5% annually, also in keeping with the assumptions of the DA model above.
Statistical analysis. The c 2 test was used to compare demographic, comorbidity, smoking history, surgical history, actual treatment received, postoperative complications at follow-up, and death data of smokers vs nonsmokers. Analysis of variance was used to compare cQoL scores between revascularized smokers and nonrevascularized smokers as well as between initial nonsmokers who did vs did not relapse to smoking. For this univariate analysis, the primary outcome (cQoL score) was reported according to the patient's status at the last follow-up. In addition, data on patient status from all visits was used to generate mean cQoL and mean change in cQoL from baseline. Secondary outcomes of patency, limb salvage, overall survival, AFS, and major adverse limb event were analyzed with KaplanMeier life-table analysis using the log-rank test. (Fig 1) . Patients who underwent any type of revascularization had better cQoL than those who did not, regardless of smoking status (Fig 2) . Among initial smokers who eventually underwent intervention, including five who developed critical limb ischemia, cQoL was not significantly different from initial nonsmoking patients (0.77 [IQR, 0.73-0.84] vs 0.73 [IQR, 0.73-0.73]; P ¼ .37). Among patients who underwent intervention, the cQoL of patients smoking at the time of their last follow-up was not significantly worse than those who were not smoking. There were no significant differences among smokers between those who underwent an operation and those who did not (0.77 [IQR, 0.73-0.84] vs 0.73 [IQR, 0.73-0.73]; P ¼ .37). Any differences in secondary outcomes by 3 years between smokers and nonsmokers, overall, as well as among those undergoing intervention, were not statistically significant (Table III) . Although 26% of initial smokers at presentation had stopped by the time of their last follow-up, some initially nonsmoking patients (10%) were noted to be smoking after their intervention.
RESULTS
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DISCUSSION
The intent of the current study was not to demonstrate that smoking cessation is unnecessary or superfluous. Cessation of smoking is not only important and to be encouraged in the long-term, representing the greatest potentially modifiable, behavioral cause of death worldwide, but cessation also reduces the perioperative risk of complications, as long as surgery is not performed within the first month after cessation when pulmonary complications are greatest, although this latter belief has recently been challenged. 2, [16] [17] [18] Cessation is cost effective in reducing health costs, more so than even the treatment of other risk factors. 19 Compared with never smokers, health care costs during the first year after hospital discharge for an inpatient surgical procedure are higher for current smokers, although less so compared with former smokers. 20 It has even become a component of hospital accreditation. 21 Smoking cessation is an important yet difficult component of the total treatment of the patient with peripheral vascular disease in which the vascular surgeon can play a very important role. 22 Simple cessation can actually improve symptoms of claudication, increasing walking distance without any other intervention. 4 As many as 45% of patients in the Northern New England report were able to quite within the first year of intervention, with success for patients undergoing lower extremity bypass (46%) better than after carotid stenting (27%) but not as good as after open abdominal aortic aneurysm repair (49%). 13 In fact, the effect of an impending vascular intervention can have value as a tool to improve the chance of smoking cessation. 23 Although the odds of successful cessation appear to be greater the more invasive the procedure, even using planned endovascular intervention as a "teachable moment" to reduce smoking may have a benefit. 24 Treatment for patients with symptoms of PAD of the lower extremities limited to claudication includes management of risk factors with exercise, diet, and medical therapy, or direct revascularization by open or endovascular (catheter-based) means. [25] [26] [27] In general, the risk of subsequent limb loss due to gangrene in patients with claudication is relatively low and is not diminished by direct interventions to improve perfusion, although rarely will intervention in patients with symptoms limited to claudication result in limb loss due to complications from attempted revascularization. Because patients who actively smoke tobacco after lower extremity revascularization procedures for claudication suffer from graft or endovascular failure, including limb loss, at accelerated rates compared with nonsmokers, refraining from direct revascularization in patients with claudication who continue to smoke is common practice.
The wisdom of withholding care may be called into question, however. Many patients who initially stopped smoking, perhaps to qualify for an intervention, will experience recidivism and return to smoking. 28 If cessation is not accomplished at least 1 month before the operation, the risk of perioperative pulmonary complications is much greater. 29 In fact, the potential negative effects of smoking remain up to 1 year or more after actual smoking cessation. 30 In addition, many patients who initially stop smoking may resume tobacco use postoperatively, counteracting the original intent. Even if a patient with vascular disease stops smoking, unless all others in his or her proximity also refrain from smoking, the benefit may be limited because of the effects of second-hand smoke. 31 Use of this patient-individualized Markov-based DA model to define expected QoL has demonstrated that overall expected patient QoL gains that are achieved with direct revascularization more than compensate for an anticipated inferior outcome with regards to patency and limb salvage, at least over 3 years of follow-up. In fact, it appears from the prevalence of open and endovascular interventions reported in the various registries that this may already be a moot point, because a large number of vascular specialists have already chosen not to withhold treatment for claudication in active smokers.
This study has a number of limitations. The DA model was used to assess whether smoking patients with claudication might be predicted to enjoy better QoL if they underwent direct revascularization, despite worse anticipated patency and limb salvage associated with active smoking, compared with how they would fare with medical therapy, alone. Of course, not all patients offered direct revascularization would choose to accept this advice, as was observed among 10% of the nonsmoking patients in this study.
Smoking status was not confirmed with biochemical testing, and it is possible that a number of patients who claimed to be nonsmokers at presentation or at the time of follow-up were, in fact, actively smoking. 32 Measurement of cotinine has been found to be more accurate than history, alone, although false positives can be frequently present in African Americans, men, in association with certain dietary items, and in patients undergoing nicotine replacement therapies as an adjunct to smoking cessation as well as with electronic cigarettes. 33, 34 As in other studies of intervention for PAD, patients in the current study who were smokers were more likely to be younger and less likely to suffer from diabetes, hypertension, or hyperlipidemia, all of which might bias the smoking group in favor of better outcomes. 5, 30 The failure to actually detect differences in AFS at 3 years between the 30 patients smoking initially or at the time of follow-up and the 141 nonsmokers is in conflict with other studies showing higher rates of limb loss, perhaps due to a type II statistical error, and may affect the findings of this study. In addition, QoL measures were not obtained directly from the patients. Methods to evaluate the outcome of intervention are primarily aimed toward revascularization. [35] [36] [37] [38] [39] [40] [41] [42] Unfortunately, standard instruments used to measure health-related QoL and disease-specific QoL prove to be quite cumbersome for use in the clinical setting and often require a capacity for abstract thinking that may be challenging for some patients. 43, 44 Therefore, cQoL was used as an outcome measure to reflect patient health-replated QoL because it does not require prospective direct testing of patients but rather can be applied retrospectively and has been shown to correlate with other more commonly reported outcomes. 6, 14 Finally, although the actual outcomes of intervention were done using life-table methods to 3 years, adverse events can certainly occur beyond this time. This may partially account for the lack of lower AFS survival observed in smokers, contrary to prior reports. Nonetheless, the DA model analysis continued through the theoretical remaining lifetime of >99% of patients and assumed higher amputation rates and inferior long-term patency after intervention than in nonsmokers. The current study by no means provides a definitive answer to this question. Ideally, direct determination of QoL performed in prospective studies of smokers with symptoms of PAD limited to claudication who are randomized to medical therapy only vs direct revascularization would be necessary to provide a clearer answer to this issue.
CONCLUSIONS
Significant recidivism for smoking occurs among patients who have stopped smoking before receiving revascularization. At least through 3 years, patients with claudication who continue to smoke may benefit more from revascularization than medical therapy alone. The strategy not to directly intervene on smokers with claudication does not appear to maximize patient QoL in the midterm. Open surgery
